格隆汇7月31日丨药明康德(02359.HK)发布公告，2025年7月31日(交易时间前)，公司与配售代理(即摩根士丹利、花旗、高盛及汇丰)订立配售协议，据此，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使承配人按照配售协议所载条款及条件，按每股配售股份配售价104.27港元合共认购7380万股新H股。
配售股份数目分别占：(a)截至本公告日期现有已发行H股总数及现有已发行股份总数约19.07%及2.57%；及(b)紧随完成后经发行配售股份扩大后的已发行H股总数及已发行股份总数约16.01%及2.51%。配售股份将根据一般授权予以发行。配售毋须股东另行批准。公司将向香港联交所上市委员会申请批准配售股份上市及买卖。
假设所有配售股份获悉数认购，配售的募集资金总额预计将约为77.0亿港元。配售的募集资金净额预计约为76.5亿港元，将按以下方式投入使用：(a)约90%将用于加速推进全球布局和产能建设；及(b)约10%将用于一般公司用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.